IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CAPETTI, AMEDEO FERDINANDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.639
EU - Europa 1.517
AS - Asia 910
SA - Sud America 116
AF - Africa 61
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.264
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.535
CN - Cina 413
GB - Regno Unito 405
IT - Italia 277
DE - Germania 219
SG - Singapore 161
SE - Svezia 118
IN - India 117
CA - Canada 91
NL - Olanda 83
FR - Francia 75
BR - Brasile 66
RU - Federazione Russa 65
ES - Italia 55
IE - Irlanda 53
HK - Hong Kong 39
JP - Giappone 31
ID - Indonesia 30
TR - Turchia 29
DK - Danimarca 27
BE - Belgio 23
FI - Finlandia 22
ZA - Sudafrica 20
PL - Polonia 19
KR - Corea 18
AU - Australia 16
CO - Colombia 16
AR - Argentina 14
TW - Taiwan 14
CH - Svizzera 13
MX - Messico 12
PH - Filippine 12
UA - Ucraina 12
VE - Venezuela 11
ET - Etiopia 10
AT - Austria 9
GR - Grecia 9
PT - Portogallo 9
TH - Thailandia 9
CL - Cile 7
CZ - Repubblica Ceca 7
UG - Uganda 7
PK - Pakistan 6
BW - Botswana 5
IR - Iran 5
MK - Macedonia 5
IL - Israele 4
RO - Romania 4
EU - Europa 3
MY - Malesia 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
TZ - Tanzania 3
BG - Bulgaria 2
BJ - Benin 2
CY - Cipro 2
GM - Gambi 2
KE - Kenya 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
NG - Nigeria 2
ZW - Zimbabwe 2
AL - Albania 1
BY - Bielorussia 1
CM - Camerun 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
GE - Georgia 1
GH - Ghana 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
MW - Malawi 1
NP - Nepal 1
PA - Panama 1
PY - Paraguay 1
RS - Serbia 1
TM - Turkmenistan 1
TN - Tunisia 1
UZ - Uzbekistan 1
VN - Vietnam 1
Totale 4.265
Salva come PNG Salva come JPEG
Città #
Southend 298
Chandler 203
Singapore 123
Milan 117
Houston 114
Fairfield 108
Frankfurt am Main 98
Redwood City 90
Ashburn 73
Seattle 72
Beijing 64
Toronto 57
Princeton 51
Wilmington 51
Dublin 49
Ann Arbor 47
Woodbridge 44
Shanghai 43
Cambridge 39
Council Bluffs 36
Nanjing 30
Boardman 27
Santa Clara 27
Hong Kong 26
Dearborn 25
Jakarta 24
Bengaluru 21
Brussels 21
Des Moines 20
New York 19
Warsaw 18
Mumbai 17
Rotterdam 17
Los Angeles 16
Helsinki 15
Jinan 15
Kiez 15
Mountain View 13
Phoenix 13
Shenyang 13
Cangzhou 11
Nuremberg 11
Guangzhou 10
Kunming 10
Ottawa 10
Taipei 10
Barcelona 9
Fuzhou 9
Istanbul 9
Nanchang 9
Nihon'odori 9
São Paulo 9
Athens 8
Central District 8
Duncan 8
London 8
Munro 8
Rome 8
Santiago de Cali 8
Changsha 7
Delhi 7
Hyderabad 7
The Dalles 7
Falls Church 6
Fremont 6
Manchester 6
New Haven 6
Nürnberg 6
Oxford 6
Berlin 5
Cergy 5
Duisburg 5
Gaborone 5
La Jolla 5
Madrid 5
Montréal 5
Málaga 5
Philadelphia 5
Piscataway 5
Quanzhou 5
San Diego 5
Santiago 5
Skopje 5
Wenzhou 5
Ahmedabad 4
Bartlesville 4
Brisbane 4
Chengdu 4
Chennai 4
Columbus 4
Glenwood 4
Hangzhou 4
Hebei 4
Kampala 4
Lubbock 4
New Delhi 4
Newark 4
Nora 4
Norwalk 4
Paris 4
Totale 2.544
Salva come PNG Salva come JPEG
Nome #
Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients 723
Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders 470
Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art 331
Antiretroviral therapy through barriers : a prominent role for nanotechnology in HIV-1 eradication from sanctuaries 316
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial 279
Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies : evidence from Phase I studies in healthy volunteers 190
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 177
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 171
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 140
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents 138
Cohort profile : The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 135
Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers : a randomized, open-label, 2-period, single-dose, crossover phase 1 study 117
Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects : an Italian cohort 107
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 100
Dolutegravir plus rilpivirine as a switch option in cART-experienced patients : 96-week data 93
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 83
OPERA : responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy 82
Brief Report : Impact of the COVID-19 Pandemic on Virological Suppression in People Living With HIV Attending a Large Italian HIV Clinic 82
Effects of ritonavir and cobicistat on dolutegravir exposure : when the booster can make the difference 80
OPERA : use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients 78
Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study 74
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study 73
Concomitant diagnosis of sexually transmitted infections and human monkeypox in patients attending a sexual health clinic in Milan, Italy 68
Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides 67
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? 65
Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects 59
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 57
Analyzing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicenter cohort of virologically-suppressed PLWHIV 43
Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort 37
One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG 31
Totale 4.466
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.730
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.730
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020190 0 0 0 0 0 0 0 0 0 93 61 36
2020/2021479 33 38 25 38 38 60 44 45 50 40 38 30
2021/2022554 61 35 34 33 30 38 45 39 89 38 21 91
2022/2023647 69 89 66 69 46 113 15 49 47 18 38 28
2023/2024565 37 53 38 51 123 63 20 34 26 25 41 54
2024/2025673 38 84 23 113 88 57 34 79 48 109 0 0
Totale 4.466